Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

Expert Opinion on Biological Therapy
Manisha Patel, David A Kaufman

Abstract

Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however, these infants remain at high risk for developing nosocomial infections associated with increased morbidity and mortality. The ability of antistaphylococcal immunoglobulins, Altastaph and INH A-2, to augment the neonatal immune system to prevent infections has been studied and evaluated in a 2009 Cochrane review. Our objective is to evaluate the safety and efficacy of a third antistaphylococcal immunoglobulin, pagibaximab, in the prevention of staphylococcal infection in preterm infants. Three studies of pagibaximab, Phases I, II and III, were examined in terms of study design, pharmacokinetics, development of sepsis and adverse effects. These studies demonstrated safety and tolerability of pagibaximab with no observed reduction in sepsis. Reported adverse events in both treatment and placebo groups were similar and consistent with events commonly observed in VLBW infants. Antistaphylococcal immunoglobulins alone have been unsuccessful in preventing nosocomial infections. Further investigations need to evaluate any potential immunomodulating products in preterm animal models prior to human studies. Future studies are...Continue Reading

References

Jul 7, 1988·The New England Journal of Medicine·M M EiblA Rosenkranz
May 29, 2004·Current Opinion in Infectious Diseases·Leonard E Weisman
Apr 7, 2006·Journal of Perinatology : Official Journal of the California Perinatal Association·D K BenjaminUNKNOWN S. aureus prevention investigators
Mar 10, 2009·International Immunopharmacology·Leonard E WeismanJames J Mond
Oct 8, 2009·JAMA : the Journal of the American Medical Association·Paolo ManzoniUNKNOWN Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology
Aug 25, 2010·Pediatrics·Barbara J StollUNKNOWN Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
Oct 4, 2011·The New England Journal of Medicine·UNKNOWN INIS Collaborative GroupWilliam Tarnow-Mordi
Mar 1, 2012·The Journal of Infectious Diseases·Christian TheilackerJohannes Huebner
Oct 19, 2012·Archives of Disease in Childhood. Fetal and Neonatal Edition·Robert Carr
Aug 13, 2013·Clinical & Developmental Immunology·Melanie R Power CoombsOfer Levy

❮ Previous
Next ❯

Citations

Aug 22, 2017·Frontiers in Microbiology·Marina Sabaté BrescóT Fintan Moriarty
Dec 4, 2019·Expert Review of Clinical Pharmacology·Susanna Esposito, Nicola Principi
Feb 23, 2017·Frontiers in Pediatrics·Steven L RaymondLyle L Moldawer
Jun 6, 2020·Human Vaccines & Immunotherapeutics·Bahman MirzaeiSina Valinejad
Feb 24, 2017·Maternal Health, Neonatology and Perinatology·Jayashree Ramasethu
Aug 4, 2018·Frontiers in Pediatrics·Simone S SchüllerOfer Levy
Feb 6, 2020·Expert Opinion on Pharmacotherapy·Federico CarboneAmirhossein Sahebkar
Jun 21, 2017·Journal of Leukocyte Biology·Emma de JongAndrew Currie
Feb 10, 2021·Pathogens·Angela FrançaLuís D R Melo
Jun 1, 2021·Frontiers in Pharmacology·Bingqing YangYuan Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.